Inactive Instrument

Cardiovascular Systems, Inc.

Equities

CSII

US1416191062

Medical Equipment, Supplies & Distribution

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Orbusneich Medical Group Holdings Limited and Cardiovascular Systems, Inc. Enters into an Amendment to Distribution Agreement CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P Healthcare Equipment Select Industry Index CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P Composite 1500 CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P 600 CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P Global BMI Index CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P 1000 CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P TMI Index CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P 600 Health Care CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from NASDAQ Composite Index CI
Abbott Laboratories completed the acquisition of Cardiovascular Systems, Inc. from The Vanguard Group, Inc. and others. CI
Wall St dips as Treasury yields rise after auction RE
Wall St dips as Treasury yields rise after auction RE
Wall St dips as Treasury yields rise; Disney hits 5-month high RE
Top Midday Gainers MT
Wall St dips as Alphabet extends fall; Disney hits 5-month high RE
Sector Update: Health Care Stocks Mixed Premarket Thursday MT
Top Premarket Gainers MT
Abbott Laboratories Enters Deal to Acquire Cardiovascular Systems for $890 Million MT
North American Morning Briefing : Stocks Seen -2- DJ
North American Morning Briefing : Stocks Seen Bouncing Back, Next Catalysts Eyed DJ
Cardiovascular Systems Shares Soar Premarket on Abbott Buyout DJ
Cardiovascular Systems Fiscal Q2 Loss, Revenue Increases; Shares Rise Pre-Bell MT
EMEA Morning Briefing : Investors to Parse Fed -2- DJ
Abbott Laboratories to Acquire Cardiovascular Systems At Equity Value of $890 Million DJ
Cardiovascular Systems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Chart Cardiovascular Systems, Inc.
More charts
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company has developed orbital atherectomy systems (OAS) for both peripheral and coronary clinical applications. The primary base of its business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. Its peripheral artery disease (PAD) products are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee, including calcified plaque. Its coronary artery disease (CAD) product, the Diamondback 360 Coronary OAS (Coronary OAS), is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.
More about the company
  1. Stock
  2. Equities
  3. Stock Cardiovascular Systems, Inc. - Nasdaq
  4. News Cardiovascular Systems, Inc.
  5. Cardiovascular Systems Reports Fiscal Q2 loss as Revenue Declines